文献速递神经肿瘤

胶质瘤中JAM-A的表达及其预后价值

Expression and prognostic value of JAM-A in gliomas.
PubMed 文献 · J Neurooncol · 2017-07-04

研究通过免疫组化和定量图像分析评估胶质瘤中JAM-A蛋白表达,发现胶质母细胞瘤中JAM-A染色强度高于低级别胶质瘤,且与CD133、SOX2、nestin和GFAP共表达,但在WHO II级和III级胶质瘤中未发现JAM-A表达与总生存的关联。

要点

  • 胶质母细胞瘤中JAM-A表达强度高于低级别胶质瘤。
  • 胶质母细胞瘤中JAM-A与CD133、SOX2、nestin、GFAP共表达。
  • WHO II级和III级胶质瘤中JAM-A表达与总生存无显著关联。

核心结论

  • JAM-A在胶质母细胞瘤中的表达高于低级别胶质瘤,并与公认的干细胞标志物共定位,提示JAM-A与胶质瘤侵袭性相关。
  • 在WHO II级和III级胶质瘤中未发现JAM-A表达与总生存的显著关联。
  • 需要进一步研究以确定JAM-A在胶质瘤中的功能和临床影响。

研究设计与样本

  • 采用免疫组织化学和先进定量图像分析(连续估计染色强度)评估胶质瘤中JAM-A蛋白表达。
  • 研究聚焦于WHO II级和III级胶质瘤的预后价值,并对胶质母细胞瘤进行双免疫荧光染色。

主要发现

  • JAM-A抗体在不同胶质瘤亚型的肿瘤细胞膜和细胞质中呈不同程度染色,胶质母细胞瘤中染色强度高于低级别胶质瘤。
  • 在II级和III级肿瘤患者中未检测到JAM-A表达与总生存的关联。
  • 胶质母细胞瘤双免疫荧光染色显示JAM-A与CD133、SOX2、nestin和GFAP在肿瘤细胞中共表达,并与微胶质/巨噬细胞标志物IBA-1有一定共表达。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究以确定JAM-A在胶质瘤中的功能和临床影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gliomas are among the most lethal cancers, being highly resistant to both chemo- and radiotherapy. The expression of junctional adhesion molecule-A (JAM-A) was recently identified on the surface of stem cell-like brain tumor-initiating cells and suggested to function as a unique glioblastoma niche adhesion factor influencing the tumorigenic potential of brain tumor-initiating cells. We have recently identified high JAM-A expression to be associated with poor outcome in glioblastomas, and our aim was to further investigate the expression of JAM-A in gliomas focusing especially on the prognostic value in WHO grade II and III gliomas. JAM-A protein expression was evaluated by immunohistochemistry and advanced quantitative image analysis with continuous estimates of staining intensity. The JAM-A antibody stained tumor cell membranes and cytoplasm to various extent in different glioma subtypes, and the intensity was higher in glioblastomas than low-grade gliomas. We could not detect an association with overall survival in patients with grade II and III tumors. Double-immunofluorescence stainings in glioblastomas revealed co-expression of JAM-A with CD133, SOX2, nestin, and GFAP in tumor cells as well as some co-expression with the microglial/macrophage marker IBA-1. In conclusion, JAM-A expression was higher in glioblastomas compared to low-grade gliomas and co-localized with recognized stem cell markers suggesting an association of JAM-A with glioma aggressiveness. No significant association between JAM-A expression and overall survival was found in grade II and III gliomas. Further research is needed to determine the function and clinical impact of JAM-A in gliomas.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Rosager AM, Sørensen MD, Dahlrot RH, et al. Expression and prognostic value of JAM-A in gliomas. J Neurooncol. 2017. PMID: 28677106. doi:10.1007/s11060-017-2555-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。